Parkinson's Disease Market (U.S., EU5, Japan) to Reach USD 9.74 Billion by 2030

Sub-Headline: The Parkinson's Disease Market across the 6/8 major pharmaceutical markets (U.S., Germany, France, U.K., Italy, Spain & Japan) is projected to grow from USD 6.56 billion in 2023 to USD 9.74 billion by 2030, registering a CAGR of 5.8%, driven by rising disease prevalence, improved diagnosis, and breakthrough neuroprotective and regenerative therapies.

Introduction
The Parkinson's Disease (PD) Market in the 6/8 major markets is undergoing significant transformation as new drug classes, gene therapies, stem-cell-based interventions, and AI-assisted monitoring systems emerge. Parkinson's disease remains the second most common neurodegenerative condition, affecting millions across the U.S., Europe, and Japan.

As aging populations rise and healthcare systems expand access to advanced PD therapies, demand for next-generation therapeutics-including continuous levodopa delivery devices, dopamine agonists, MAO-B inhibitors, A2A antagonists, and innovative disease-modifying therapies-continues to accelerate.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73647

Key Takeaways
• Market Size (2023): USD 6.56 Billion
• Expected Market Size (2030): USD 9.74 Billion
• CAGR (2024-2030): 5.8%
• Growth driven by long-acting levodopa, infusion systems, and high-value neuroprotective therapies.
• Leading companies include AbbVie, Novartis, GSK, Teva Pharmaceuticals, UCB, Biogen, Amneal Pharmaceuticals, Acorda Therapeutics, Neurocrine Biosciences, and Merck.
• Sharp rise in clinical R&D for LRRK2 inhibitors, α-synuclein-targeted immunotherapies, gene therapies, and stem-cell-based regenerative treatments.

Market Story
The Parkinson's Disease treatment paradigm is undergoing a shift from decades of symptom-focused management to true disease-modifying therapy development.
1. Strong Growth in Long-Acting & Continuous Delivery Formulations
Newer solutions address "wearing-off" and motor fluctuations:
• Extended-release levodopa/carbidopa
• Subcutaneous infusion pumps
• Transdermal systems and inhaled formulations
These reduce "off" time and improve daily living performance.

2. Gene Therapy Innovation Accelerates
Companies are advancing:
• AAV-based gene therapies that stimulate dopamine production
• LRRK2 genetic pathway inhibitors
• GBA-targeted therapies for genetically linked PD forms
These therapies aim to slow or modify disease progression.

3. Stem Cell & Regenerative Therapies Gain Momentum
Clinical programs are exploring:
• Dopaminergic neuron transplants
• iPSC-based regenerative cell therapies
• Neurotrophic factor-mediated neural repair
Japan and the U.K. are leading early-stage approvals in regenerative neurology.

4. AI-Driven Remote Monitoring & Digital Neurology
Wearables and mobile platforms support:
• Tremor & gait analysis
• Medication response modeling
• Real-time symptom monitoring
• Tele-neurology management
These technologies enhance patient outcomes and reduce clinic burden.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/73647/parkinson-s-disease-in-68-market

Market Segments
By Drug Class
• Levodopa/Carbidopa Combinations (dominant segment)
• Dopamine Agonists
• MAO-B Inhibitors
• COMT Inhibitors
• A2A Receptor Antagonists
• Anticholinergics
• VMAT2 Inhibitors
• Emerging Neuroprotective & Disease-Modifying Therapies

By Route of Administration
• Oral
• Injectable
• Transdermal
• Inhalation
• Implantable & Continuous Infusion Devices

By Patient Stage
• Early-Stage Parkinson's Disease
• Mid-Stage Parkinson's Disease
• Advanced Parkinson's Disease with Motor Complications

By Region (6/8 Markets)
• United States (largest share; >55% of total market value)
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Recent Developments
• AbbVie advanced next-generation Duopa/Duodopa delivery systems for better motor control.
• UCB progressed its α-synuclein antibody into later-phase trials.
• Amneal launched enhanced extended-release levodopa products for longer on-time.
• Biogen expanded its neurodegenerative portfolio through acquisitions and partnerships.
• GSK invested in novel mitochondrial stabilization drug platforms.
• Teva strengthened its global distribution of PD symptomatic therapies.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73647

Expert Quote
"Parkinson's disease care is entering a new era, marked by the rise of regenerative therapies, precision diagnostics, and long-acting drug delivery systems. These advancements are creating strong clinical and commercial momentum across major global markets."
-Irfan Tamboli, Business Development Executive, Exactitude Consultancy

Market Drivers
• Rising prevalence across aging populations
• Progress in neuroprotective & disease-modifying pipelines
• Rapid adoption of infusion pumps, patches & digital neurology solutions
• Growing investment in gene therapy & regenerative medicine
• Improved reimbursement and access in U.S., EU5 & Japan
• Increased clinical trials for LRRK2, α-synuclein & A2A targets

Forecast Outlook
The market will exceed USD 9.74 billion by 2030, driven by:
• Launch of advanced neurotherapeutics
• Rising biologics and gene therapy approvals
• High adoption of long-acting levodopa products
• Expansion of specialty neurology centers

Regional Highlights
• U.S. dominates due to high therapy uptake and advanced neurology infrastructure.
• EU5 shows strong biosimilar and specialty-care growth.
• Japan leads Asia in regenerative neurology, driving faster adoption.

Government & Regulatory Initiatives
• FDA breakthrough designations for neuroprotective therapies
• EMA support for advanced therapy medicinal products (ATMPs)
• Japan PMDA leadership in stem-cell therapy approvals
• NIH & EU Horizon neuroscience funding
• National Parkinson's awareness & early diagnosis programs

Conclusion
The Parkinson's Disease Market across the 6/8 global markets is evolving quickly, driven by precision neurology, regenerative medicine, advanced drug-delivery platforms, and strong R&D pipelines. Companies focusing on disease-modifying therapies and next-generation formulations will lead the market through 2030.

This report is also available in the following languages : Japanese (68の市場におけるパーキンソン病), Korean (68년 시장의 파킨슨병), Chinese (68 市场中的帕金森病), French (Maladie de Parkinson sur 68 marchés), German (Parkinson-Krankheit im 68. Markt), and Italian (Malattia di Parkinson nel mercato 68), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73647

Our More Reports:

Aseptic Filling Machine Market
https://exactitudeconsultancy.com/reports/73535/aseptic-filling-machine-market

Non-Viral Transfection Reagents Market
https://exactitudeconsultancy.com/reports/73537/non-viral-transfection-reagents-market

Cell Sorting Market
https://exactitudeconsultancy.com/reports/73539/cell-sorting-market

Pharmaceutical Spray Drying Market
https://exactitudeconsultancy.com/reports/73539/cell-sorting-market

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

This release was published on openPR.